Prenetics Global (NASDAQ:PRE – Get Free Report) and Standard BioTools (NASDAQ:LAB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Profitability
This table compares Prenetics Global and Standard BioTools’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -229.17% | -15.70% | -12.98% |
| Standard BioTools | -79.92% | -27.05% | -15.52% |
Earnings and Valuation
This table compares Prenetics Global and Standard BioTools”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $21.74 million | 1.89 | -$62.72 million | ($3.23) | -1.39 |
| Standard BioTools | $106.34 million | 5.99 | -$74.66 million | ($0.71) | -2.41 |
Insider & Institutional Ownership
25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 53.1% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Prenetics Global and Standard BioTools, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 0 | 0 | 1 | 0 | 3.00 |
| Standard BioTools | 0 | 0 | 2 | 0 | 3.00 |
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 100.00%. Standard BioTools has a consensus target price of $2.88, indicating a potential upside of 68.13%. Given Prenetics Global’s higher possible upside, analysts clearly believe Prenetics Global is more favorable than Standard BioTools.
Volatility and Risk
Prenetics Global has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Summary
Standard BioTools beats Prenetics Global on 8 of the 12 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Standard BioTools
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
